<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071406</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18786</org_study_id>
    <secondary_id>CA209-737</secondary_id>
    <nct_id>NCT03071406</nct_id>
  </id_info>
  <brief_title>Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma</brief_title>
  <official_title>A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs
      nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy
      (SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it
      will stimulate the body's immune system to work against tumor cells. This study will test an
      investigational use of nivolumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomly assigned in a 1:1 ratio to Arm A (nivolumab + ipilimumab), or Arm B (nivolumab + ipilimumab + SBRT).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Objective-response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: including Complete Response (CR) rate, Partial Response (PR) rate, and Stable Disease (SD) rate will be calculated through exact binomial distribution with a 2-sided 95% confidence interval among patients who obtain a least one dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>Median Progression Free Survival with 95% Confidence Interval. Progression is defined as progressive tumor lesions per immune-related Response Evaluation in Solid Tumors (irRECIST) definition, or appearance of one or more new Merkel cell carcinoma lesions, which can be local or distant in location from the irradiated lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Median Overall Survival with 95% Confidence Interval. The length of time from the start of treatment until death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.</description>
    <arm_group_label>Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 1 mg/kg/dose IV q6 weeks.</description>
    <arm_group_label>Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <other_name>YERVOY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <description>Stereotactic Body Radiation Therapy 24Gy in 3 fractions.</description>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status less than 2

          -  Active disease measurable by CT or MRI

          -  Prior chemotherapy or immunotherapy will be allowed if new or persistent measurable
             site(s) of disease are present.

          -  Prior radiation therapy will be allowed if active measurable disease was not
             previously treated with radiation therapy.

          -  Must be either recurrent or Stage IV American Joint Committee on Cancer (AJCC) (7th
             edition) and have histologically confirmed Merkel cell carcinoma with at least 2
             distinct lesions in order to be eligible.

          -  Must have at least 2 distinct lesions as documented by a complete physical examination
             and imaging studies within 4 weeks prior to randomization. Imaging studies must
             include a diagnostic CT scan of the involved disease sites and all known sites of
             resected disease and brain magnetic resonance (MRI) or CT (brain CT allowable if MRI
             is contraindicated or if there is no known history of resected brain lesions).

          -  Tumor tissue from the core biopsy or resected site of disease must be provided for
             biomarker analyses.

        Exclusion Criteria:

          -  History of Grade 3 toxicity or use of infliximab with prior immunotherapy

          -  Patients with brain metastasis.

          -  Active, known, or suspected autoimmune disease. Potential participants with type I
             diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only
             requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or
             alopecia) not requiring systemic treatment are permitted to enroll.

          -  Patients with prior history of non-Merkel cell carcinoma malignancies are excluded
             except adequately treated basal cell, squamous cell skin cancer, chronic lymphocytic
             leukemia or other indolent diseases not requiring therapy; adequately treated, with
             curative intent, cancer from which the patient is currently in complete remission per
             investigator's judgment; or patients with history of breast cancer and no evidence of
             disease on hormonal therapy to prevent recurrence and patients with prostate cancer on
             adjuvant hormonal therapy with undetectable PSA are eligible.

          -  A condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily
             prednisone equivalent) or other immunosuppressive medications within 14 days of
             randomization. Inhaled or topical steroids are permitted in the absence of active
             autoimmune disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sungjune Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Austin Lannon</last_name>
    <phone>813-745-2169</phone>
    <email>austin.lannon@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sungjune Kim</last_name>
    <phone>813-745-7898</phone>
    <email>sungjune.kim@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Austin Lannon</last_name>
      <phone>813-745-2169</phone>
      <email>austin.lannon@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Sungjune Kim, M.D., Ph.D.</last_name>
      <phone>813-745-7898</phone>
      <email>sungjune.kim@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sungjune Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jimmy Caudell, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikhil Khushalani, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Messina, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trevor Rose, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis Harrison, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Markowitz, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Brohl, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeynep Eroglu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evan Wuthrick, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Merkel cell carcinoma (MCC)</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Metastasis</keyword>
  <keyword>Stereotactic body radiation therapy (SBRT)</keyword>
  <keyword>Immunology</keyword>
  <keyword>Antibody</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Metastatic skin cancer</keyword>
  <keyword>Cutaneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

